查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1301159

生物技術和製藥服務外包市場規模、份額和趨勢分析報告：按服務、最終用途、地區、細分市場趨勢：2023-2030

Biotechnology And Pharmaceutical Services Outsourcing Market Size, Share & Trends Analysis Report By Services (Consulting, Auditing & Assessment), By End-use (Pharma, Biotech), By Region, And Segment Forecasts, 2023 - 2030
出版日期: | 出版商: Grand View Research | 英文 133 Pages | 商品交期: 2-10個工作天內

價格

生物技術和製藥服務外包市場增長和趨勢

GrandView Research, Inc.最新報告顯示，到2030年，全球生物技術和醫藥服務外包市場預計將達到1079.6億美元。

預計 2023 年至 2030 年該市場將以 5.3% 的複合年增長率增長。COVID-19 大流行對生物技術和製藥第三方服務提供商和臨床試驗產生了重大影響，導致試驗延遲、中斷和取消。大流行的復甦導致更多地採用基於機器學習 (ML) 的平台、人工智能 (AI)、藥品製造自動化和創新研究設計，這將在未來幾年改變 CRO 和 CMO 的格局。預料到的。

在競爭日益激烈的環境中，企業正在專注於其核心競爭力，以最大限度地提高資源利用率並促進創新。通過外包非核心職能，我們專注於藥物開發和發現等核心能力。因此，一些製藥公司正在與各種外包服務提供商合作進行新藥開發。例如，2022 年 1 月，單克隆抗體開發商 HaemaLogiX 與 Lonza 建立合作夥伴關係，生產 KappaMab 單克隆抗體，這是一種治療骨髓瘤的候選藥物。生物製藥和製藥公司對再生醫學等新穎和創新療法的投資以及藥物開發服務正在推動研發活動。

對生物製劑和小分子的高需求導致生物技術和藥品製造的合同製造組織 (CMO) 和合同製造組織 (CRO) 服務組合不斷增長。較小的製藥/生物技術公司可能需要大量的專業知識或昂貴的能力來進行自己的開發、製造、監管事務、產品維護、產品設計、開發、產品測試、驗證、培訓和教育。我們正面臨著短缺等挑戰。其結果是為 CMO 和 CRO 的發展提供了有利可圖的機會。外包服務正在不斷增長，並變得更具戰略性、針對性和計劃性。

這些因素預計將在提高 CMO/CRO 的整體市場份額方面發揮關鍵作用。價格競爭加劇、監管挑戰和專利到期正在降低生物技術和製藥行業的利潤。有競爭力的服務被認為是公司之間的“戰略競爭優勢”，因為它們有助於克服這些問題。這些服務為我們的客戶節省了成本，因為從長遠來看，選擇可持續的供應商將帶來成本節省。它還有助於節省運營和管理生產和研究設施的時間。研發和製造承包可以降低產品開發成本和產品製造成本。

此外，外包服務有助於克服貿易壁壘，使企業更容易進入國外市場。由於這些優勢，一些企業選擇外包服務，而不是投資生產設備和僱用技術工人。此外，市場上的幾家主要參與者正在實施各種戰略舉措，例如合作夥伴關係、推出、合併和收購，以擴大其在市場上的服務。例如，2022年4月，Covance母公司LabCorp與細胞和基因治療技術開發商Xcell Biosciences合作，擴大其細胞和基因治療研究能力。根據該協議，Labcorp 和 Xcellbio 將合作開展旨在提高細胞和基因療法的功效和安全性的項目。

生物技術和製藥服務外包市場報告亮點

  • 由於欺詐案件增加、知識產權差異和技術創新不斷增加，預計到 2022 年，諮詢領域將以 19.6% 的份額主導市場。
  • 按服務劃分，在發展中地區對仿製藥和生物仿製藥的日益關注的推動下，其他細分市場預計在預測期內將以 5.3% 的最高複合年增長率增長。
  • 由於價格壓力增加和仿製藥的興起，製藥公司大量外包其內部業務，預計製藥行業在預測期內將以 5.5% 的複合年增長率增長。
  • 另一方面，生物技術領域佔有很大的市場份額。這是由於生物技術產品的不斷增長。
  • 北美地區主導市場，2022 年收入份額最大，達到 53.5%。這是由於該地區擁有大量的生物技術和製藥公司以及 CRO 和 CMO 提供的高質量服務。
  • 由於監管框架的改善、成本節約的巨大潛力以及廉價熟練勞動力的可用性，亞太地區預計在預測期內復合年增長率最高，達到 5.8%。
  • 市場主要參與者已採取多項戰略舉措來增加其在市場上的影響力。例如，2023年2月，專門從事先進藥物輸送解決方案的生物技術公司Elektrofi與Thermo Fisher Scientific簽訂了合同製造協議。此次合作將利用 Thermo Fisher Scientific 的合同製造服務專業知識來支持 Electrophy 的藥物輸送技術。

目錄

第一章 調查方法和範圍

  • 市場細分和範圍
  • 調查方法
    • 信息採購
  • 信息或數據分析
  • 調查方法
  • 調查範圍和假設
  • 市場形成和驗證
  • 國家/地區份額的計算
  • 數據源列表

第二章執行摘要

  • 市場展望
  • 分部展望
  • 區域洞察力
  • 競爭考慮
  • 生物技術和製藥服務外包市場概況
  • 生物技術和醫藥服務外包細分市場概況
  • 生物技術和醫藥服務外包市場競爭格局概覽

3.生物技術和製藥服務外包市場變量、趨勢和範圍

  • 市場譜系展望
  • 市場動態
    • 市場驅動力分析
    • 市場約束因素分析
  • 生物技術和製藥服務外包市場分析工具
    • 行業分析-波特分析
    • PESTEL 分析
    • 最終用途識別分析
    • 服務價格分析

第四章生物技術和醫藥服務外包市場：服務評估和趨勢分析

  • 細分儀表板
  • 生物技術和醫藥服務外包市場：2022年和2030年服務波動分析
  • 諮詢
    • 2018-2030 年諮詢市場收入估算和預測
    • 合規性
    • 修理
    • 質量管理體系諮詢
    • 其他
  • 審計與評估
    • 2018-2030 年審計和評估市場收入估算和預測
  • 藥事事務
    • 2018-2030 年監管市場收入估計和預測
    • 臨床試驗提交和產品註冊
    • 修理
    • 監管寫作和發布
    • 其他
  • 產品維護
  • 產品設計與開發
  • 產品測試和驗證
  • 培訓和教育
  • 其他

第五章生物技術和醫藥服務外包市場：最終用途估計和趨勢分析

  • 細分儀表板
  • 生物技術和製藥服務外包市場：2022 年和 2030 年最終用途變化分析
  • 製藥公司
  • 生物技術公司

第六章生物技術和醫藥服務外包市場：區域估計和趨勢分析

  • 生物技術和製藥服務外包市場：2022 年和 2030 年區域變化分析
  • 北美
    • 監管框架
    • 2018-2030 年北美生物技術和製藥服務外包市場估計和預測
    • 美國
    • 加拿大
  • 歐洲
    • 監管框架
    • 2018-2030 年歐洲生物技術和製藥服務外包市場估計和預測
    • 英國
    • 德國
    • 法國
    • 意大利
    • 西班牙
    • 丹麥
    • 瑞典
    • 挪威
  • 亞太地區
    • 監管框架
    • 2018-2030 年亞太地區生物技術和製藥服務外包市場估計和預測
    • 日本
    • 中國
    • 印度
    • 澳大利亞
    • 泰國
    • 韓國
  • 拉丁美洲
    • 監管框架
    • 2018-2030 年拉丁美洲生物技術和製藥服務外包市場估計和預測
    • 巴西
    • 墨西哥
    • 阿根廷
  • 中東和非洲
    • 監管框架
    • 中東和非洲生物技術和製藥服務外包市場估計和預測，2018-2030
    • 南非
    • 沙特阿拉伯
    • 阿拉伯聯合酋長國
    • 科威特

第7章 競爭格局

  • 企業分類
  • 2022 年公司市場份額分析
  • 戰略規劃
  • 公司簡介/名單
    • The Quantic Group
    • IQVIA HOLDINGS, INC.
    • Parexel International Corporation
    • Lachman Consultant Services
    • GMP Pharmaceuticals
    • Concept Heidelberg GmbH
    • Covance, INC.
    • Charles River
    • PRA Health Sciences
    • ICON plc.
Product Code: GVR-1-68038-326-3

Biotechnology And Pharmaceutical Services Outsourcing Market Growth & Trends

The global biotechnology and pharmaceutical services outsourcing market size is expected to reach USD 107.96 billion by 2030, according to a new report by Grand View Research, Inc. The market is expected to grow at a CAGR of 5.3% from 2023 to 2030. The COVID-19 pandemic has significantly impacted biotechnology and pharmaceutical third-party service providers as well as clinical trials, resulting in trial delays, suspensions, and terminations. The recovery from the pandemic has led to the increasing adoption of Machine Learning (ML)-based platforms, Artificial Intelligence (AI), automation in drug manufacturing, and innovative trial designs that are projected to transform the CRO and CMO landscape in the coming years.

With rising competitiveness, companies are concentrating on their core capabilities to maximize resources and foster innovation. Focus on their key competencies, such as the development and discovery of new medicines, by outsourcing non-core functions. As a result, several pharmaceutical companies collaborate with various outsourcing service providers for new drug development. For instance, in January 2022, HaemaLogiX, a developer of monoclonal antibodies entered into a partnership with Lonza to manufacture a myeloma drug candidate, KappaMab monoclonal antibody. Biopharmaceutical and pharmaceutical investments in novel and innovative therapies, for instance, regenerative medicine, are driving the R&D activity together with drug development services.

The high demand for biologics along with small molecules has led to the expansion of service portfolios of Contract Manufacturing Organizations (CMOs)/Contract Research Organizations (CROs) for biotechnology and pharmaceutical production. Small pharma/biotech companies are facing challenges while performing in-house development, manufacturing, regulatory affairs, product maintenance, product design, and development, product testing and validation, and training and education, such as a lack of substantial expertise and expensive capability. This, in turn, has created lucrative opportunities for the growth of CMOs and CROs. Contract services are growing and becoming strategic, targeted, and planned.

These factors are expected to play a pivotal role in enhancing the share of CMOs/CROs in the overall market. Growing pricing pressure, regulatory challenges, and patent expiration have led to shrinking margins in the biotech and pharmaceutical industry. Contract services are considered a "strategic competitive weapon" among companies, as these services help overcome these issues. These services offer cost savings to their clients as choosing sustainable suppliers could lead to reduced costs in the long run. They also help save time utilized in the operations and management of a production and research facility. Contract research and manufacturing allow low-cost product development and the manufacturing cost of a product.

Furthermore, outsourcing services assist in overcoming trade barriers and facilitate the entry of firms into the foreign market. Owing to these advantages, several firms choose to outsource services rather than invest capital in production equipment and hiring skilled labor. Furthermore, several key entities in the market are undertaking various strategic initiatives, such as partnerships, service launches, mergers, and acquisitions, to expand their services in the market. For instance, in April 2022, LabCorp, the parent company of Covance, collaborated with a developer of cell and gene therapy technologies, Xcell Biosciences, to expand its research capabilities in cell and gene therapies. Under this agreement, Labcorp and Xcellbio would collaborate on projects aimed at improving the efficacy & safety of cell and gene therapies.

Biotechnology And Pharmaceutical Services Outsourcing Market Report Highlights

  • The consulting segment is expected to dominate the market with a share of 19.6% in 2022 owing to a rise in the number of fraudulent cases, discrepancies in intellectual property rights, and a rise in technological innovations
  • Based on service, the others segment is expected to witness the highest CAGR of 5.3% over the forecast period owing to the increasing focus on generic and biosimilar in developing regions
  • The pharma segment is expected to witness a CAGR of 5.5% over the forecast period as the pharmaceutical companies outsource internal activities at a larger scale due to rising pricing pressure, and growth of generics in the industry
  • On the other hand, the biotechnology segment held a significant share of the market. This is due to the expanding biotech product pipelines
  • North America dominated the market and accounted for the largest revenue share of 53.5% in 2022 due to the presence of a large number of biotechnology and pharmaceutical companies and the quality of services offered by the CROs and CMOs in the region
  • In Asia Pacific, the market is anticipated to register the highest CAGR of 5.8% over the forecast period owing to improved regulatory frameworks, high scope for cost savings, and the presence of cheap skilled personnel
  • The key players in the market undertaking several strategic initiatives to strengthen their market presence. For instance, in February 2023, Elektrofi, a biotech company specializing in advanced drug delivery solutions, entered into a contract manufacturing agreement with Thermo Fisher Scientific. This collaboration will leverage Thermo Fisher Scientific's expertise in contract manufacturing services to support Elektrofi's drug delivery technology

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation and Scope
  • 1.2. Research Methodology
    • 1.2.1. Information Procurement
  • 1.3. Information or Data Analysis
  • 1.4. Methodology
  • 1.5. Research Scope and Assumptions
  • 1.6. Market Formulation & Validation
      • 1.6.1.1. Country Market: CARG Calculation
  • 1.7. Country Based Segment Share Calculation
  • 1.8. List of Data Sources

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
  • 2.3. Regional Insights
  • 2.4. Competitive Insights
  • 2.5. Biotechnology and Pharmaceutical Services Outsourcing Market Snapshot
  • 2.6. Biotechnology and Pharmaceutical Services Outsourcing Market Segment Snapshot
  • 2.7. Biotechnology and Pharmaceutical Services Outsourcing Market Competitive Landscape Snapshot

Chapter 3. Biotechnology and Pharmaceutical Services Outsourcing Market Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
      • 3.2.1.1. Increasing outsourcing of R&D activities
      • 3.2.1.2. Changing regulatory landscape
      • 3.2.1.3. Increasing focus on core competencies by pharmaceutical and biotechnology companies
      • 3.2.1.4. Growing drug development costs coupled with high clinical development failure rates
      • 3.2.1.5. Increasing mergers and collaborations
    • 3.2.2. Market Restraint Analysis
      • 3.2.2.1. Monitoring issues and lack of standardization
      • 3.2.2.2. Loss of control
      • 3.2.2.3. Data security issues
  • 3.3. Biotechnology and Pharmaceutical Services Outsourcing Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
      • 3.3.1.1. Bargaining power of the suppliers
      • 3.3.1.2. Bargaining power of the buyers
      • 3.3.1.3. Threats of substitution
      • 3.3.1.4. Threats from new entrants
      • 3.3.1.5. Competitive rivalry
    • 3.3.2. PESTEL Analysis
      • 3.3.2.1. Political landscape
      • 3.3.2.2. Economic and Social landscape
      • 3.3.2.3. Technological landscape
    • 3.3.3. End-use Perception Analysis
      • 3.3.3.1. Why do you outsource Biotechnology and Pharmaceutical services to CROs?
      • 3.3.3.2. Percentage of outsourcing of different services.
      • 3.3.3.3. Importance of CRO selection parameters (Ranking from 1 to 5, where 1 - least important and 5 - most important).
    • 3.3.4. Service Price Analysis
      • 3.3.4.1. Pricing strategy
      • 3.3.4.1.1. Transactional business models
      • 3.3.4.1.2. Performance-based business models
      • 3.3.4.1.3. Outcome-based business models
      • 3.3.4.2. Consulting rates
      • 3.3.4.3. Heat map for pricing analysis

Chapter 4. Biotechnology and Pharmaceutical Services Outsourcing Market: Service Estimates & Trend Analysis

  • 4.1. Segment Dashboard
  • 4.2. Biotechnology and Pharmaceutical Services Outsourcing Market: Service Movement Analysis, USD Million, 2022 & 2030
  • 4.3. Consulting
    • 4.3.1. Consulting Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 4.3.2. Regulatory Compliance
      • 4.3.2.1. Regulatory Compliance Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 4.3.3. Remediation
      • 4.3.3.1. Remediation Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 4.3.4. Quality Management Systems Consulting
      • 4.3.4.1. Quality Management Systems Consulting Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 4.3.5. Others
      • 4.3.5.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.4. Auditing and Assessment
    • 4.4.1. Auditing and Assessment Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.5. Regulatory affairs
    • 4.5.1. Regulatory affairs Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 4.5.2. Clinical Trial Applications & Product Registration
      • 4.5.2.1. Clinical Trial Applications & Product Registration Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 4.5.3. Remediation
      • 4.5.3.1. Remediation Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 4.5.4. Regulatory Writing & Publishing
      • 4.5.4.1. Regulatory Writing & Publishing Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 4.5.5. Others
      • 4.5.5.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.6. Product Maintenance
    • 4.6.1. Product Maintenance Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.7. Product Design & Development
    • 4.7.1. Product Design & Development Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.8. Product Testing & Validation
    • 4.8.1. Product Testing & Validation Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.9. Training & Education
    • 4.9.1. Training & Education Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.10. Others
    • 4.10.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 5. Biotechnology and Pharmaceutical Services Outsourcing Market: End-Use Estimates & Trend Analysis

  • 5.1. Segment Dashboard
  • 5.2. Biotechnology and Pharmaceutical Services Outsourcing Market: End-Use Movement Analysis, USD Million, 2022 & 2030
  • 5.3. Pharmaceutical Companies
    • 5.3.1. Pharmaceutical Companies Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.4. Biotech Companies
    • 5.4.1. Biotech Companies Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 6. Biotechnology and Pharmaceutical Services Outsourcing Market: Regional Estimates & Trend Analysis

  • 6.1. Biotechnology and Pharmaceutical Services Outsourcing Market: Regional Movement Analysis, 2022 & 2030
  • 6.2. North America
    • 6.2.1. Regulatory Framework
    • 6.2.2. North America Biotechnology and Pharmaceutical Services Outsourcing Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 6.2.3. U.S.
      • 6.2.3.1. Key Country Dynamics
      • 6.2.3.2. Competitive Scenario
      • 6.2.3.3. U.S. Biotechnology and Pharmaceutical Services Outsourcing Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 6.2.4. Canada
      • 6.2.4.1. Key Country Dynamics
      • 6.2.4.2. Competitive Scenario
      • 6.2.4.3. Canada Biotechnology and Pharmaceutical Services Outsourcing Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 6.3. Europe
    • 6.3.1. Regulatory Framework
    • 6.3.2. Europe Biotechnology and Pharmaceutical Services Outsourcing Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 6.3.3. UK
      • 6.3.3.1. Key Country Dynamics
      • 6.3.3.2. Competitive Scenario
      • 6.3.3.3. UK Biotechnology and Pharmaceutical Services Outsourcing Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 6.3.4. Germany
      • 6.3.4.1. Key Country Dynamics
      • 6.3.4.2. Competitive Scenario
      • 6.3.4.3. Germany Biotechnology and Pharmaceutical Services Outsourcing Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 6.3.5. France
      • 6.3.5.1. Key Country Dynamics
      • 6.3.5.2. Competitive Scenario
      • 6.3.5.3. Prevalence Insights
      • 6.3.5.4. France Biotechnology and Pharmaceutical Services Outsourcing Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 6.3.6. Italy
      • 6.3.6.1. Key Country Dynamics
      • 6.3.6.2. Competitive Scenario
      • 6.3.6.3. Prevalence Insights
      • 6.3.6.4. Italy Biotechnology and Pharmaceutical Services Outsourcing Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 6.3.7. Spain
      • 6.3.7.1. Key Country Dynamics
      • 6.3.7.2. Competitive Scenario
      • 6.3.7.3. Prevalence Insights
      • 6.3.7.4. Spain Biotechnology and Pharmaceutical Services Outsourcing Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 6.3.8. Denmark
      • 6.3.8.1. Key Country Dynamics
      • 6.3.8.2. Competitive Scenario
      • 6.3.8.3. Prevalence Insights
      • 6.3.8.4. Denmark Biotechnology and Pharmaceutical Services Outsourcing Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 6.3.9. Sweden
      • 6.3.9.1. Key Country Dynamics
      • 6.3.9.2. Competitive Scenario
      • 6.3.9.3. Prevalence Insights
      • 6.3.9.4. Sweden Biotechnology and Pharmaceutical Services Outsourcing Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 6.3.10. Norway
      • 6.3.10.1. Key Country Dynamics
      • 6.3.10.2. Competitive Scenario
      • 6.3.10.3. Prevalence Insights
      • 6.3.10.4. Norway Biotechnology and Pharmaceutical Services Outsourcing Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 6.4. Asia Pacific
    • 6.4.1. Regulatory Framework
    • 6.4.2. Asia Pacific Biotechnology and Pharmaceutical Services Outsourcing Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 6.4.3. Japan
      • 6.4.3.1. Key Country Dynamics
      • 6.4.3.2. Competitive Scenario
      • 6.4.3.3. Prevalence Insights
      • 6.4.3.4. Japan Biotechnology and Pharmaceutical Services Outsourcing Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 6.4.4. China
      • 6.4.4.1. Key Country Dynamics
      • 6.4.4.2. Competitive Scenario
      • 6.4.4.3. Prevalence Insights
      • 6.4.4.4. China Biotechnology and Pharmaceutical Services Outsourcing Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 6.4.5. India
      • 6.4.5.1. Key Country Dynamics
      • 6.4.5.2. Competitive Scenario
      • 6.4.5.3. Prevalence Insights
      • 6.4.5.4. India Biotechnology and Pharmaceutical Services Outsourcing Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 6.4.6. Australia
      • 6.4.6.1. Key Country Dynamics
      • 6.4.6.2. Competitive Scenario
      • 6.4.6.3. Prevalence Insights
      • 6.4.6.4. Australia Biotechnology and Pharmaceutical Services Outsourcing Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 6.4.7. Thailand
      • 6.4.7.1. Key Country Dynamics
      • 6.4.7.2. Competitive Scenario
      • 6.4.7.3. Prevalence Insights
      • 6.4.7.4. Thailand Biotechnology and Pharmaceutical Services Outsourcing Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 6.4.8. South Korea
      • 6.4.8.1. Key Country Dynamics
      • 6.4.8.2. Competitive Scenario
      • 6.4.8.3. Prevalence Insights
      • 6.4.8.4. South Korea Biotechnology and Pharmaceutical Services Outsourcing Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 6.5. Latin America
    • 6.5.1. Regulatory Framework
    • 6.5.2. Latin America Biotechnology and Pharmaceutical Services Outsourcing Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 6.5.3. Brazil
      • 6.5.3.1. Key Country Dynamics
      • 6.5.3.2. Competitive Scenario
      • 6.5.3.3. Brazil Biotechnology and Pharmaceutical Services Outsourcing Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 6.5.4. Mexico
      • 6.5.4.1. Key Country Dynamics
      • 6.5.4.2. Competitive Scenario
      • 6.5.4.3. Mexico Biotechnology and Pharmaceutical Services Outsourcing Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 6.5.5. Argentina
      • 6.5.5.1. Key Country Dynamics
      • 6.5.5.2. Competitive Scenario
      • 6.5.5.3. Argentina Biotechnology and Pharmaceutical Services Outsourcing Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 6.6. Middle East & Africa
    • 6.6.1. Regulatory Framework
    • 6.6.2. Middle East & Africa Biotechnology and Pharmaceutical Services Outsourcing Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 6.6.3. South Africa
      • 6.6.3.1. Key Country Dynamics
      • 6.6.3.2. Competitive Scenario
      • 6.6.3.3. South Africa Biotechnology and Pharmaceutical Services Outsourcing Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 6.6.4. Saudi Arabia
      • 6.6.4.1. Key Country Dynamics
      • 6.6.4.2. Competitive Scenario
      • 6.6.4.3. Saudi Arabia Biotechnology and Pharmaceutical Services Outsourcing Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 6.6.5. UAE
      • 6.6.5.1. Key Country Dynamics
      • 6.6.5.2. Competitive Scenario
      • 6.6.5.3. UAE Biotechnology and Pharmaceutical Services Outsourcing Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 6.6.6. Kuwait
      • 6.6.6.1. Key Country Dynamics
      • 6.6.6.2. Competitive Scenario
      • 6.6.6.3. Kuwait Biotechnology and Pharmaceutical Services Outsourcing Market Estimates And Forecasts, 2018 - 2030 (USD Million)

Chapter 7. Competitive Landscape

  • 7.1. Company Categorization
  • 7.2. Company Market Share Analysis, 2022
  • 7.3. Strategy Mapping
  • 7.4. Company Profiles/Listing
    • 7.4.1. The Quantic Group
      • 7.4.1.1. Overview
      • 7.4.1.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 7.4.1.3. Product Benchmarking
      • 7.4.1.4. Strategic Initiatives
    • 7.4.2. IQVIA HOLDINGS, INC.
      • 7.4.2.1. Overview
      • 7.4.2.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 7.4.2.3. Product Benchmarking
      • 7.4.2.4. Strategic Initiatives
    • 7.4.3. Parexel International Corporation
      • 7.4.3.1. Overview
      • 7.4.3.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 7.4.3.3. Product Benchmarking
      • 7.4.3.4. Strategic Initiatives
    • 7.4.4. Lachman Consultant Services
      • 7.4.4.1. Overview
      • 7.4.4.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 7.4.4.3. Product Benchmarking
      • 7.4.4.4. Strategic Initiatives
    • 7.4.5. GMP Pharmaceuticals
      • 7.4.5.1. Overview
      • 7.4.5.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 7.4.5.3. Product Benchmarking
      • 7.4.5.4. Strategic Initiatives
    • 7.4.6. Concept Heidelberg GmbH
      • 7.4.6.1. Overview
      • 7.4.6.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 7.4.6.3. Product Benchmarking
      • 7.4.6.4. Strategic Initiatives
    • 7.4.7. Covance, INC.
      • 7.4.7.1. Overview
      • 7.4.7.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 7.4.7.3. Product Benchmarking
      • 7.4.7.4. Strategic Initiatives
    • 7.4.8. Charles River
      • 7.4.8.1. Overview
      • 7.4.8.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 7.4.8.3. Product Benchmarking
      • 7.4.8.4. Strategic Initiatives
    • 7.4.9. PRA Health Sciences
      • 7.4.9.1. Overview
      • 7.4.9.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 7.4.9.3. Product Benchmarking
      • 7.4.9.4. Strategic Initiatives
    • 7.4.10. ICON plc.
      • 7.4.10.1. Overview
      • 7.4.10.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 7.4.10.3. Product Benchmarking
      • 7.4.10.4. Strategic Initiatives

List of Tables

  • Table 1 List of secondary sources
  • Table 2 List of abbreviations
  • Table 3 Global Biotechnology and Pharmaceutical Services Outsourcing Market, By Region, 2018 - 2030 (USD Million)
  • Table 4 Global Biotechnology and Pharmaceutical Services Outsourcing Market, By Services, 2018 - 2030 (USD Million)
  • Table 5 Global Biotechnology and Pharmaceutical Services Outsourcing Market, By End Use, 2018 - 2030 (USD Million)
  • Table 6 North America Biotechnology and Pharmaceutical Services Outsourcing Market, By Country, 2018 - 2030 (USD Million)
  • Table 7 North America Biotechnology and Pharmaceutical Services Outsourcing Market, By Services, 2018 - 2030 (USD Million)
  • Table 8 North America Biotechnology and Pharmaceutical Services Outsourcing Market, By End Use, 2018 - 2030 (USD Million)
  • Table 9 U.S. Biotechnology and Pharmaceutical Services Outsourcing Market, by Services, 2018 - 2030 (USD Million)
  • Table 10 U.S. Biotechnology and Pharmaceutical Services Outsourcing Market, by End Use, 2018 - 2030 (USD Million)
  • Table 11 Canada Biotechnology and Pharmaceutical Services Outsourcing Market, by Services, 2018 - 2030 (USD Million)
  • Table 12 Canada Biotechnology and Pharmaceutical Services Outsourcing Market, by End Use, 2018 - 2030 (USD Million)
  • Table 13 Europe Biotechnology and Pharmaceutical Services Outsourcing Market, by Country, 2018 - 2030 (USD Million)
  • Table 14 Europe Biotechnology and Pharmaceutical Services Outsourcing Market, by Services, 2018 - 2030 (USD Million)
  • Table 15 Europe Biotechnology and Pharmaceutical Services Outsourcing Market, by End Use, 2018 - 2030 (USD Million)
  • Table 16 UK Biotechnology and Pharmaceutical Services Outsourcing Market, by Services, 2018 - 2030 (USD Million)
  • Table 17 UK Biotechnology and Pharmaceutical Services Outsourcing Market, by End Use, 2018 - 2030 (USD Million)
  • Table 18 Germany Biotechnology and Pharmaceutical Services Outsourcing Market, by Services, 2018 - 2030 (USD Million)
  • Table 19 Germany Biotechnology and Pharmaceutical Services Outsourcing Market, by End Use, 2018 - 2030 (USD Million)
  • Table 20 France Biotechnology and Pharmaceutical Services Outsourcing Market, by Services, 2018 - 2030 (USD Million)
  • Table 21 France Biotechnology and Pharmaceutical Services Outsourcing Market, by End Use, 2018 - 2030 (USD Million)
  • Table 22 Italy Biotechnology and Pharmaceutical Services Outsourcing Market, by Services, 2018 - 2030 (USD Million)
  • Table 23 Italy Biotechnology and Pharmaceutical Services Outsourcing Market, by End Use, 2018 - 2030 (USD Million)
  • Table 24 Spain Biotechnology and Pharmaceutical Services Outsourcing Market, by Services, 2018 - 2030 (USD Million)
  • Table 25 Spain Biotechnology and Pharmaceutical Services Outsourcing Market, by End Use, 2018 - 2030 (USD Million)
  • Table 26 Denmark Biotechnology and Pharmaceutical Services Outsourcing Market, by Services, 2018 - 2030 (USD Million)
  • Table 27 Denmark Biotechnology and Pharmaceutical Services Outsourcing Market, by End Use, 2018 - 2030 (USD Million)
  • Table 28 Sweden Biotechnology and Pharmaceutical Services Outsourcing Market, by Services, 2018 - 2030 (USD Million)
  • Table 29 Sweden Biotechnology and Pharmaceutical Services Outsourcing Market, by End Use, 2018 - 2030 (USD Million)
  • Table 30 Norway Biotechnology and Pharmaceutical Services Outsourcing Market, by Services, 2018 - 2030 (USD Million)
  • Table 31 Norway Biotechnology and Pharmaceutical Services Outsourcing Market, by End Use, 2018 - 2030 (USD Million)
  • Table 32 Asia Pacific Biotechnology and Pharmaceutical Services Outsourcing Market, by Country, 2018 - 2030 (USD Million)
  • Table 33 Asia Pacific Biotechnology and Pharmaceutical Services Outsourcing Market, by Services, 2018 - 2030 (USD Million)
  • Table 34 Asia Pacific Biotechnology and Pharmaceutical Services Outsourcing Market, by End Use, 2018 - 2030 (USD Million)
  • Table 35 Japan Biotechnology and Pharmaceutical Services Outsourcing Market, by Services, 2018 - 2030 (USD Million)
  • Table 36 Japan Biotechnology and Pharmaceutical Services Outsourcing Market, by End Use, 2018 - 2030 (USD Million)
  • Table 37 China Biotechnology and Pharmaceutical Services Outsourcing Market, by Services, 2018 - 2030 (USD Million)
  • Table 38 China Biotechnology and Pharmaceutical Services Outsourcing Market, by End Use, 2018 - 2030 (USD Million)
  • Table 39 India Biotechnology and Pharmaceutical Services Outsourcing Market, by Services, 2018 - 2030 (USD Million)
  • Table 40 India Biotechnology and Pharmaceutical Services Outsourcing Market, by End Use, 2018 - 2030 (USD Million)
  • Table 41 Australia Biotechnology and Pharmaceutical Services Outsourcing Market, by Services, 2018 - 2030 (USD Million)
  • Table 42 Australia Biotechnology and Pharmaceutical Services Outsourcing Market, by End Use, 2018 - 2030 (USD Million)
  • Table 43 Thailand Biotechnology and Pharmaceutical Services Outsourcing Market, by Services, 2018 - 2030 (USD Million)
  • Table 44 Thailand Biotechnology and Pharmaceutical Services Outsourcing Market, by End Use, 2018 - 2030 (USD Million)
  • Table 45 South Korea Biotechnology and Pharmaceutical Services Outsourcing Market, by Services, 2018 - 2030 (USD Million)
  • Table 46 South Korea Biotechnology and Pharmaceutical Services Outsourcing Market, by End Use, 2018 - 2030 (USD Million)
  • Table 47 Latin America Biotechnology and Pharmaceutical Services Outsourcing Market, by Country, 2018 - 2030 (USD Million)
  • Table 48 Latin America Biotechnology and Pharmaceutical Services Outsourcing Market, by Services, 2018 - 2030 (USD Million)
  • Table 49 Latin America Biotechnology and Pharmaceutical Services Outsourcing Market, by End Use, 2018 - 2030 (USD Million)
  • Table 50 Brazil Biotechnology and Pharmaceutical Services Outsourcing Market, by Services, 2018 - 2030 (USD Million)
  • Table 51 Brazil Biotechnology and Pharmaceutical Services Outsourcing Market, by End Use, 2018 - 2030 (USD Million)
  • Table 52 Mexico Biotechnology and Pharmaceutical Services Outsourcing Market, by Services, 2018 - 2030 (USD Million)
  • Table 53 Mexico Biotechnology and Pharmaceutical Services Outsourcing Market, by End Use, 2018 - 2030 (USD Million)
  • Table 54 Argentina Biotechnology and Pharmaceutical Services Outsourcing Market, by Services, 2018 - 2030 (USD Million)
  • Table 55 Argentina Biotechnology and Pharmaceutical Services Outsourcing Market, by End Use, 2018 - 2030 (USD Million)
  • Table 56 MEA Biotechnology and Pharmaceutical Services Outsourcing Market, by Country, 2018 - 2030 (USD Million)
  • Table 57 MEA Biotechnology and Pharmaceutical Services Outsourcing Market, by Services, 2018 - 2030 (USD Million)
  • Table 58 MEA Biotechnology and Pharmaceutical Services Outsourcing Market, by End Use, 2018 - 2030 (USD Million)
  • Table 59 South Africa Biotechnology and Pharmaceutical Services Outsourcing Market, by Services, 2018 - 2030 (USD Million)
  • Table 60 South Africa Biotechnology and Pharmaceutical Services Outsourcing Market, by End Use, 2018 - 2030 (USD Million)
  • Table 61 South Arabia Biotechnology and Pharmaceutical Services Outsourcing Market, by Services, 2018 - 2030 (USD Million)
  • Table 62 South Arabia Biotechnology and Pharmaceutical Services Outsourcing Market, by End Use, 2018 - 2030 (USD Million)
  • Table 63 UAE Biotechnology and Pharmaceutical Services Outsourcing Market, by Services, 2018 - 2030 (USD Million)
  • Table 64 UAE Biotechnology and Pharmaceutical Services Outsourcing Market, by End Use, 2018 - 2030 (USD Million)
  • Table 65 Kuwait Biotechnology and Pharmaceutical Services Outsourcing Market, by Services, 2018 - 2030 (USD Million)
  • Table 66 Kuwait Biotechnology and Pharmaceutical Services Outsourcing Market, by End Use, 2018 - 2030 (USD Million)
  • Table 67 Participant's overview
  • Table 68 Financial performance
  • Table 69 Key companies undergoing expansions
  • Table 70 Key companies undergoing acquisitions
  • Table 71 Key companies undergoing collaborations
  • Table 72 Key companies launching new products/services
  • Table 73 Key companies undergoing partnerships
  • Table 74 Key companies undertaking other strategies

List of Figures

  • Fig. 1 Market segmentation
  • Fig. 2 Market research process
  • Fig. 3 Data triangulation techniques
  • Fig. 4 Primary research pattern
  • Fig. 5 Market research approaches
  • Fig. 6 Value-chain-based sizing & forecasting
  • Fig. 7 QFD modeling for market share assessment
  • Fig. 8 Market formulation and validation
  • Fig. 9 Commodity flow analysis
  • Fig. 10 Biotechnology and Pharmaceutical Services Outsourcing Market Outlook, 2018 - 2030 (USD Million)
  • Fig. 11 Biotechnology and Pharmaceutical Services Outsourcing Market Summary, 2021 (USD Million)
  • Fig. 12 Market trends & outlook
  • Fig. 13 Parent Market Outlook
  • Fig. 14 Ancillary Market Outlook
  • Fig. 15 Market driver analysis (Current & future impact)
  • Fig. 16 Market restraint analysis (Current & future impact)
  • Fig. 17 Company market position analysis
  • Fig. 18 Biotechnology and Pharmaceutical Services Outsourcing market, service outlook key takeaways (USD Million)
  • Fig. 19 Biotechnology and Pharmaceutical Services Outsourcing market: Service movement analysis (USD Million)
  • Fig. 20 Consulting market, 2018 - 2030 (USD Million)
  • Fig. 21 Regulatory compliance market, 2018 - 2030 (USD Million)
  • Fig. 22 Remediation market, 2018 - 2030 (USD Million)
  • Fig. 23 Quality management systems market, 2018 - 2030 (USD Million)
  • Fig. 24 Other consulting market, 2018 - 2030 (USD Million)
  • Fig. 25 Auditing and assessment market, 2018 - 2030 (USD Million)
  • Fig. 26 Regulatory affairs market, 2018 - 2030 (USD Million)
  • Fig. 27 Clinical trial applications & product registration market, 2018 - 2030 (USD Million)
  • Fig. 28 Regulatory writing & publishing market, 2018 - 2030 (USD Million)
  • Fig. 29 Legal representation market, 2018 - 2030 (USD Million)
  • Fig. 30 Other regulatory affairs market, 2018 - 2030 (USD Million)
  • Fig. 31 Product maintenance market, 2018 - 2030 (USD Million)
  • Fig. 32 Product design & development market, 2018 - 2030 (USD Million)
  • Fig. 33 Product testing & validation market, 2018 - 2030 (USD Million)
  • Fig. 34 Training & education market, 2018 - 2030 (USD Million)
  • Fig. 35 Others market, 2018 - 2030 (USD Million)
  • Fig. 36 Biotechnology and pharmaceutical services outsourcing market: End Use movement analysis
  • Fig. 37 Biotechnology and pharmaceutical services outsourcing market End Use outlook: Key takeaways
  • Fig. 38 Pharma market, 2018 - 2030 (USD Million)
  • Fig. 39 Biotech market, 2018 - 2030 (USD Million)
  • Fig. 40 Regional outlook, 2018 & 2030
  • Fig. 41 Regional market dashboard
  • Fig. 42 Regional market place: Key takeaways
  • Fig. 43 North America biotechnology and pharmaceutical services outsourcing market, 2018 - 2030 (USD Million)
  • Fig. 44 U.S. biotechnology and pharmaceutical services outsourcing market, 2018 - 2030 (USD Million)
  • Fig. 45 Canada biotechnology and pharmaceutical services outsourcing market, 2018 - 2030 (USD Million)
  • Fig. 46 Europe biotechnology and pharmaceutical services outsourcing market, 2018 - 2030 (USD Million)
  • Fig. 47 UK biotechnology and pharmaceutical services outsourcing market, 2018 - 2030 (USD Million)
  • Fig. 48 Germany biotechnology and pharmaceutical services outsourcing market, 2018 - 2030 (USD Million)
  • Fig. 49 France biotechnology and pharmaceutical services outsourcing market, 2018 - 2030 (USD Million)
  • Fig. 50 Italy biotechnology and pharmaceutical services outsourcing market, 2018 - 2030 (USD Million)
  • Fig. 51 Spain biotechnology and pharmaceutical services outsourcing market, 2018 - 2030 (USD Million)
  • Fig. 52 Denmark biotechnology and pharmaceutical services outsourcing market, 2018 - 2030 (USD Million)
  • Fig. 53 Sweden biotechnology and pharmaceutical services outsourcing market, 2018 - 2030 (USD Million)
  • Fig. 54 Norway biotechnology and pharmaceutical services outsourcing market, 2018 - 2030 (USD Million)
  • Fig. 55 Asia Pacific biotechnology and pharmaceutical services outsourcing market, 2018 - 2030 (USD Million)
  • Fig. 56 Japan biotechnology and pharmaceutical services outsourcing market, 2018 - 2030 (USD Million)
  • Fig. 57 China (Mainland) biotechnology and pharmaceutical services outsourcing market, 2018 - 2030 (USD Million)
  • Fig. 58 India biotechnology and pharmaceutical services outsourcing market, 2018 - 2030 (USD Million)
  • Fig. 59 Australia biotechnology and pharmaceutical services outsourcing market, 2018 - 2030 (USD Million)
  • Fig. 60 Thailand biotechnology and pharmaceutical services outsourcing market, 2018 - 2030 (USD Million)
  • Fig. 61 South Korea biotechnology and pharmaceutical services outsourcing market, 2018 - 2030 (USD Million)
  • Fig. 62 Latin America biotechnology and pharmaceutical services outsourcing market, 2018 - 2030 (USD Million)
  • Fig. 63 Brazil biotechnology and pharmaceutical services outsourcing market, 2018 - 2030 (USD Million)
  • Fig. 64 Mexico biotechnology and pharmaceutical services outsourcing market, 2018 - 2030 (USD Million)
  • Fig. 65 Argentina biotechnology and pharmaceutical services outsourcing market, 2018 - 2030 (USD Million)
  • Fig. 66 MEA biotechnology and pharmaceutical services outsourcing market, 2018 - 2030 (USD Million)
  • Fig. 67 South Africa biotechnology and pharmaceutical services outsourcing market, 2018 - 2030 (USD Million)
  • Fig. 68 Saudi Arabia biotechnology and pharmaceutical services outsourcing market, 2018 - 2030 (USD Million)
  • Fig. 69 UAE biotechnology and pharmaceutical services outsourcing market, 2018 - 2030 (USD Million)
  • Fig. 70 Kuwait biotechnology and pharmaceutical services outsourcing market, 2018 - 2030 (USD Million)